NCT00427362View on ClinicalTrials.gov

A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)

PHASE3CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

May 31, 2007

Conditions
Psoriatic Arthritis
Interventions
DRUG

Adalimumab

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY

NCT00427362 - A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM) | Biotech Hunter | Biotech Hunter